Technology Overview:Synbal is commercializing a CRISPR-based breakthrough technology developed at UCSD.The technology involves "Active" genetic elements with the unique capability of self-replicating with high efficiency and specificity.Active Genetics:The technology introduces the concept of "Active Genetics," which overrides the natural rules of inheritance described by Mendel.This results in a novel seamless form of inheritance.Potential Impact:The technology has the potential to dramatically accelerate genetic manipulations in laboratory settings.It offers game-changing approaches to improve patient-specificity and enhance the efficiency and functionality of cell-therapy strategies.University Collaboration:The breakthrough technology originated from the work of biologists at UCSD.This advancement in genetic technology, particularly the concept of "Active Genetics," has significant implications for genetic research and therapy. The ability to manipulate genes with high efficiency and specificity can pave the way for transformative approaches in both laboratory settings and clinical applications. If you have any specific questions or if there's more you'd like to share about Synbal or the technology, feel free to provide additional details!

Advisory Role:Advised the Dean of the Division of Physical Sciences at UC San Diego.Involved in projects aimed at promoting collaboration among various centers and institutes.Collaboration Promotion:Focused on promoting collaboration both locally and internationally.Emphasized collaboration among scientists who share interests and possess complementary expertise.Innovation and Entrepreneurship:Noted a penchant for innovation within the division.Mentioned that this innovation has led to the establishment of companies by current and former faculty.Economic Impact:Highlighted the central role that these faculty-founded companies have played in the development of San Diego’s technology-based economy.

Problem Addressed:MessageDoc aimed to tackle the challenge of the lack of electronic communication tools in healthcare.Specifically targeted communication gaps among care providers from different organizations with varying EMR systems and interactions between providers and patients.Solution - MessageDoc™:Developed MessageDoc™ as a digital health solution to address the communication challenges.MessageDoc™ provides HIPAA-compliant communications, ensuring the security and privacy of patient information.Communication Features:MessageDoc™ offers various communication channels, including "instant" audio, video, text, and forms-based messaging.These features enable efficient and secure communication within healthcare provider organizations, between different provider organizations, and with patients.Workload Reduction:A key benefit highlighted is the reduction of the workload for doctors and staff, suggesting that MessageDoc™ streamlines communication processes and enhances overall efficiency.By offering a comprehensive and secure communication platform, MessageDoc™ appears to have addressed a significant pain point in the healthcare industry, contributing to improved collaboration and streamlined workflows among care providers and patients. If you have any specific questions or if there are additional details you'd like to share about MessageDoc or its impact, feel free to provide more information!

Invited as a protagonist on how to create a successful partnership between big pharma and biotech companies in a healthcare class taught by Professor Reggie Herzlinger.

Corporate Alliances:Negotiated and signed corporate alliances with major pharmaceutical companies such as Novartis, Pfizer, Roche, and Medarex.The potential combined value of these alliances exceeds $250 million.Fundraising:Provided strategic and operational leadership to secure over $125 million from multiple sources, including corporate collaborations, mezzanine funds, and venture capital funds.Strategic Shifts:Successfully steered the company through several significant shifts in the biotech industry.The company initially focused on gene therapy for HIV but was later repositioned as a drug target-discovery company using genomics.Subsequently, the company transitioned to drug discovery and development.

Co-founding a Purchasing Group:Played a key role in co-founding a purchasing group with four other biotech companies.The primary objective was to increase the purchasing power of the participating companies, likely leading to cost savings and other collaborative benefits.Evolution into a Regional Life Science Association:Over time, the purchasing group transformed into the largest regional life science association globally.The association now represents more than 550 member companies in Southern California.Significance of the Association:The association's growth and scope indicate its substantial impact on the life science industry in Southern California.Represents a powerful network of collaboration and support among a diverse range of life science companies.Collaborative Purchasing Power:The initial focus on purchasing power likely facilitated collaborative efforts in negotiating contracts, bulk purchases, and other cost-effective measures.representing more than 550 member companies in Southern California.

Acquisition by Philips:The company you were involved with was acquired by Philips in June 2017.The acquisition amounted to $2.1 billion, indicating the significant value and recognition of the company's contributions.Innovations at Advanced Interventional Systems (AIS):Played a role in inventing and developing the first high-power Excimer laser with transmittance through highly flexible fiber optics at Advanced Interventional Systems (AIS).AIS was later acquired by Spectranetics.First Over-the-Wire Laser Angioplasty Catheter:Developed the first over-the-wire laser angioplasty catheter designed to ablate long lesions and total occlusions in peripheral and coronary arteries.Standard-of-Care Impact:The technology and product developed have become the standard-of-care for revascularizing arteries and pacemaker lead removal.This indicates the significant impact and widespread adoption of the innovation in medical practices.

Excimer Laser Innovation:Pioneered the application of Excimer laser technology for ablating calcified lesions in both coronary and peripheral arteries.This innovation likely addressed challenges in treating patients with calcified lesions, offering a more effective and precise approach.Treatment of Coronary and Peripheral Artery Lesions:The use of Excimer laser technology for treating patients with coronary and peripheral artery lesions indicates a broad and impactful application of the technology.Angioscope Exploration:Explored the role of angioscopy in interventional cardiology.Angioscopy involves using a tiny camera to visualize the interior of blood vessels, providing real-time insights into the condition of arteries during interventions.

System Design:Designed an integrated system specifically tailored for solid-state chip manufacturing.This likely involved a comprehensive understanding of the manufacturing process and the specific requirements of the semiconductor industry.Image Processing:Implemented image processing capabilities within the system.Image processing is crucial in semiconductor manufacturing for tasks such as defect detection, quality control, and process monitoring.Pattern Recognition:Integrated pattern recognition functionality into the system.Pattern recognition is essential for identifying specific features, structures, or defects in the intricate patterns present on semiconductor wafers.Application to Solid-State Chip Manufacturing:The focus on solid-state chip manufacturing suggests the system was tailored to address challenges unique to this industry, such as the miniaturized and complex structures involved in semiconductor fabrication.